Ads
related to: clinical trials for ovarian cancer recurrencepfizerclinicaltrials.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
The rate of cancer recurrence is determined by many factors, including age, sex, cancer type, treatment duration, stage of advancement, grade of original tumor, and cancer-specific risk factors. [2] [3] [4] If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original ...
The definition of "progression" generally involves imaging techniques (plain radiograms, CT scans, MRI, PET scans, ultrasounds) or other aspects: biochemical progression may be defined on the basis of an increase in a tumor marker (such as CA125 for epithelial ovarian cancer or PSA for prostate cancer). In clinical trials, what precisely ...
Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly.Although originally thought to be a p38 mitogen-activated protein kinase (MAPK) inhibitor, [1] it has since been reported that it acts instead as an epidermal growth factor receptor (EGFR) inhibitor.
Having focused on research, the group had the first IOTA congress and the development of the IOTA website. Having established a platform of clinical research centres IOTA will be planning further studies investigating aspects of ovarian cancer management and outcome prediction.
Serous ovarian cancer is the most common type of epithelial ovarian cancer and it accounts for about two-thirds of cases of epithelial ovarian cancer. [28] Low-grade serous carcinoma is less aggressive than high-grade serous carcinomas, though it does not typically respond well to chemotherapy or hormonal treatments. [ 28 ]
Promising results have been reported from a phase II clinical trial for ovarian cancer [5] and endometrial cancer. [6] Phase II trials have also been undertaken for prostate, breast and bladder cancer, although no results for these trials have been reported in peer-reviewed literature. A phase I trial in prostate cancer indicated that nine out ...
Roughly 15% of ovarian cancers are detected at the early stage, at which the 5-year survival rate is 92%. [33] A Norwegian meta-analysis of 22 randomized studies involving early-stage ovarian cancer revealed the likelihood that 8 out of 10 women treated with cisplatin after the initial surgery were overtreated. [34]
Ovarian squamous cell carcinoma (oSCC) or squamous ovarian carcinoma (SOC) is a rare tumor that accounts for 1% of ovarian cancers. [1] Included in the World Health Organization 's classification of ovarian cancer, [ 2 ] it mainly affects women above 45 years of age.
Ads
related to: clinical trials for ovarian cancer recurrencepfizerclinicaltrials.com has been visited by 10K+ users in the past month